A local drug delivery system based on visible light-cured glycol chitosan and doxorubicin⋅hydrochloride for thyroid cancer treatment in vitro and in vivo

Drug Delivery

Hoon Hyun¹  So Yeon Kim²  Sung Ok Hong³  Deok-Won Lee⁴  Sun-Jung Yoon⁵  Youngbum Yoo⁶  Sewook Um⁷  Dae Hyeok Yang⁸ 

[1] Department of Biomedical Sciences, Chonnam National University Medical School, Gwangju, Republic of Korea;Department of Dental Hygiene College of Health Sciences, Cheongju University, Cheongju, Republic of Korea;Department of Dentistry, Catholic Kwandong University, School of Medicine, International St. Mary’s Hospital, Incheon, Republic of Korea;Department of Oral & Maxillofacial Surgery, Kyung Hee University Dental Hospital at Gangdong Kyung Hee University, Seoul, Republic of Korea;Department of Orthopedic Surgery, Research Institute of Clinical Medicine of Chonbuk National University, Biomedical Research Institute of Chonbuk National University Hospital, Jeonju, Republic of Korea;Department of Surgery, School of Medicine, The Konkuk University, Seoul, Republic of Korea;Department of Veterinary Surgery, College of Veterinary Medicine, Seoul National University, Seoul, Republic of Korea;Institute of Cell and Tissue Engineering, College of Medicine, The Catholic University of Korea, Seoul, Republic of Kore;

关键词: Glycol chitosan;    visible light irradiation;    doxorubicin⋅hydrochloride;    local drug delivery system;    thyroid cancer;   

DOI  :  10.1080/10717544.2018.1507058

来源: publisher

【 摘 要 】

Systemic drug delivery systems (SDDSs) for thyroid cancer treatment are associated with serious side effects including nausea, anorexia, and hair loss as a result of damage to normal tissues. In this study, we investigated the feasibility of a local DDS (LDDS) based on visible light-cured glycol chitosan (GC) hydrogel and doxorubicin⋅hydrochloride (DOX⋅HCl), called GC10/DOX, on thyroid cancer treatment in vivo. Visible light irradiation increased the storage modulus and swelling ratio of the GC10/DOX hydrogel precursor. The release of DOX⋅HCl from GC10/DOX exhibited two unique patterns comprising an initial burst within 18 hours, followed by a controlled and sustained release thereafter. In vitro cell viability testing showed that GC10/DOX had a greater antitumor effect than free DOX⋅HCl and GC10 hydrogel controls. In vivo, local injection of GC10/DOX near tumor tissue led to a superior antitumor effect compared with controls consisting of free DOX⋅HCl intravenously injected to the tail vein of thyroid cancer-bearing mouse and GC10 hydrogel subcutaneously injected near the tumor. Altogether, our results suggest that GC10/DOX may have clinical potential for thyroid cancer treatment.

【 授权许可】

CC BY